Japan’s Daiichi Sankyo and US-based Dana-Farber Cancer Institute have announced a preclinical research collaboration to carry out research on lung cancer.
A team of scientists from Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Belfer Center for Applied Cancer Science and Harvard Medical School will partner with Daiichi Sankyo to develop a translational pharmacology package with experimental animal and patient-derived xenograft models.
Go deeper with GlobalData
These models were established at Dana-Farber Cancer Institute.
Dana-Farber Cancer Institute Lowe Center for Thoracic Oncology director Pasi Jänne said: “We are excited to enter this unique partnership with Daiichi Sankyo.
“Working together, we can accelerate the development of new therapeutic strategies for patients with lung cancer.”
The partnership will leverage the translational medicine expertise of the Belfer Center.
Daiichi Sankyo oncology research and development executive vice-president and global head Antoine Yver said: “Despite several recent significant advances in the treatment of lung cancer with EGFR mutations, many patients still die of this disease, hence our urgency and obligation to pursue swiftly great science.
“By partnering with scientists at Dana-Farber, we are looking to better understand drivers of disease and initial and secondary resistance to established targeted treatments, with the ultimate goal of identifying a potential new treatment for patients with lung cancer.”
